Who
Jennifer Jarrett
Director, President and CEO
Company insider
Files Form 4 as: Director, President and CEO, Damora Therapeutics; Director, Zura Bio; Director, Sagimet Biosciences; Director, Syndax Pharmaceuticals; Chief Operating Officer, Arcus Biosciences; Director, Radius Health; Director, Arena Pharmaceuticals; Other, Surrozen.
In numbers
- Trades disclosed
- 135
- Buys
- 1
- Sells
- 31
- Bought
- $506K
- Sold
- $11.8M
- Companies
- 10
- Companies where not an officer
- 7
- First trade
- 7 Apr 2016
- Last trade
- 25 Sep 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 28 Sep 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Bought | $253K12,500 at $20.23 | filing |
| 25 Sep 2026filed 28 Sep 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Bought | $253K12,500 at $20.23 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,567 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,567 at $0.00 | filing |
| 30 Mar 2026filed 1 Apr 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 30 Mar 2026filed 1 Apr 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500,000 at $0.00 | filing |
| 30 Mar 2026filed 1 Apr 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500,000 at $0.00 | filing |
| 30 Mar 2026filed 1 Apr 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —126,000 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —126,000 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 17 Dec 2025filed 18 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $221K9,983 at $22.16 | filing |
| 16 Dec 2025filed 18 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $246K11,225 at $21.88 | filing |
| 7 Nov 2025filed 12 Nov 2025 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | $62K50,291 at $1.23 | filing |
| 7 Nov 2025filed 12 Nov 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code M | $62K50,291 at $1.23 | filing |
News
Valion Bio, Inc. Common Stock (NASDAQ:VBIO) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head ComparisonRCUS · themarketsdaily.com · 18 Oct 2026Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rated "Moderate Buy" by Sell-Side BrokeragesRCUS · dailypolitical.com · 16 Oct 2026
0 headlines in the last 90 days name Jennifer Jarrett; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.